Full text

Turn on search term navigation

© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Our study aims to evaluate the effect of everolimus treatment on lung function in lung transplant (LT) patients with established chronic lung allograft dysfunction (CLAD). Methods: This retrospective study included LT patients in two reference LT units who started everolimus therapy to treat CLAD from October 2008 to October 2016. We assessed the variation in the maximum forced expiratory volume in the first second (FEV1) before and after the treatment. Results: Fifty-seven patients were included in this study. The variation in the FEV1 was −102.7 (149.6) mL/month before starting everolimus compared to −44.7 (109.6) mL/month within the first three months, +1.4 (63.5) mL/month until the sixth month, and −7.4 (46.2) mL/month until the twelfth month (p < 0.05). Glomerular filtrate remained unchanged after everolimus treatment [59.1 (17.5) mL/min per 1.73 m2 at baseline and 60.9 (19.6) mL/min per 1.73 m2, 57.7 (20.5) mL/min per 1.73 m2, and 57.3 (17.8) mL/min per 1.73 m2, at 1, 3, and 6 months, respectively] (p > 0.05). Everolimus was withdrawn in 22 (38.6%) patients. The median time to withdrawal was 14.1 (5.5–25.1) months. Conclusions: This study showed an improvement in FEV1 decline in patients with CLAD treated with everolimus. However, the drug was withdrawn in a high proportion of patients.

Details

Title
Everolimus Treatment for Chronic Lung Allograft Dysfunction in Lung Transplantation
Author
Iturbe-Fernández, David 1 ; Alicia de Pablo Gafas 2 ; Mora Cuesta, Víctor Manuel 1   VIAFID ORCID Logo  ; Rodrigo Alonso Moralejo 2   VIAFID ORCID Logo  ; Carlos Andrés Quezada Loaiza 3 ; Virginia Pérez González 2 ; López-Padilla, Daniel 4 ; Cifrián, José M 1   VIAFID ORCID Logo 

 Lung Transplant Unit, Pulmonary Medicine Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain; [email protected] (V.M.M.C.); [email protected] (J.M.C.) 
 Lung Transplant Unit, Pulmonary Medicine Department, Doce de Octubre University Hospital, 28041 Madrid, Spain; [email protected] (A.d.P.G.); [email protected] (R.A.M.); [email protected] (C.A.Q.L.); [email protected] (V.P.G.) 
 Lung Transplant Unit, Pulmonary Medicine Department, Doce de Octubre University Hospital, 28041 Madrid, Spain; [email protected] (A.d.P.G.); [email protected] (R.A.M.); [email protected] (C.A.Q.L.); [email protected] (V.P.G.); CIBER Respiratory Diseases (CIBERES), Carlos III Health Institute, 28029 Madrid, Spain 
 Pulmonary Medicine Department, Gregorio Marañón University Hospital, 28007 Madrid, Spain 
First page
603
Publication year
2024
Publication date
2024
Publisher
MDPI AG
e-ISSN
20751729
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3059575141
Copyright
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.